GLP-1 drugs linked to hair loss and nail disorders
- People taking popular GLP-1 medications for obesity and type 2 diabetes experience nail detachment and hair loss at significantly higher rates than non-users, according to research presented on...
- Researchers examined fingernail health across participants recruited from France, the United States, Brazil, and Mexico.
- Charles Taïeb, a clinical dermatologist at Necker University Hospital in Paris, stated that nail changes associated with these therapies had previously been purely anecdotal.
People taking popular GLP-1 medications for obesity and type 2 diabetes experience nail detachment and hair loss at significantly higher rates than non-users, according to research presented on October 1, 2026, at the European Academy of Dermatology and Venereology Congress in Vienna. Sciencedaily.com reported that a multinational study evaluated 575 users of drugs like Ozempic, Wegovy, Mounjaro, and Zepbound alongside a control group of 1,329 individuals who had never taken the medications.
Nail Disorders and Detachment Reported Among GLP-1 Users
Researchers examined fingernail health across participants recruited from France, the United States, Brazil, and Mexico. Foxnews.com noted that 39% of GLP-1 users reported nail detachment, a condition where the nail separates from the underlying skin, compared to just 9% of non-users. Nail discoloration affected 46% of medication users versus 17% in the control group. Overall, two-thirds of GLP-1 users, or 66%, reported at least one nail disorder, compared to 53% of the control group.
Study author Dr. Charles Taïeb, a clinical dermatologist at Necker University Hospital in Paris, stated that nail changes associated with these therapies had previously been purely anecdotal. Our findings show a clear association, but they also underline an important point: Not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself,
Taïeb said in a press release.
Hair Loss and Inflammatory Scalp Symptoms
A companion study evaluating hair and scalp health found that 50% of GLP-1 users reported unusual hair loss, compared with 34% of the control group. After starting treatment, 26% of medication users reported new hair loss or thinning, compared with 12% of non-users. Reduced hair volume affected 42% of users versus 19% of controls, while scalp redness was roughly three times more frequent among those taking GLP-1 drugs.
Study author Dr. Bruno Halioua, a dermatologist in Paris, noted that hair loss was typically accompanied by inflammatory scalp symptoms such as itching, scaling, or redness. This suggests that what is happening on the scalp may go beyond the classical shedding seen after rapid weight loss and involve an inflammatory component,
Halioua said. Scalp inflammation was the rule rather than the exception, which clinicians do not currently look for and which may be treatable.
Weight Loss Does Not Fully Account for Physical Changes
Investigators examined whether rapid weight loss alone drove the observed dermatological differences, as shifting body weight can influence nutrition and hair or nail health. However, the data showed that weight loss did not fully explain the findings. Even when analysts restricted their review to participants who lost weight, GLP-1 users still reported significantly higher rates of nail and hair problems than non-users who also lost weight.
After adjusting for existing skin conditions and nutritional deficiencies, nail detachment and discoloration remained two to three times more frequent among the medication group. Investigators emphasized that the cross-sectional studies relied on patient-reported symptoms at a single point in time rather than standardized clinical examinations, meaning the results show associations rather than direct causation.
Future Research Plans and Clinical Guidance
To establish how symptoms develop over time, the research team plans to conduct prospective studies following patients from the beginning of treatment with standardized physical examinations and biological monitoring. DUCRAY Laboratories, part of the Pierre Fabre Group, provided institutional support for the research.
Medical specialists advise patients experiencing these symptoms to consult a physician rather than stopping their medication independently. These changes are frequent, usually benign, and are not a reason to stop an effective treatment on one’s own initiative,
Halioua said, adding that patients noticing hair shedding, scalp irritation, or nail changes should mention them during a doctor visit.